Navigation Links
MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results
Date:2/23/2011

MARIETTA, Ga., Feb. 23, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that its results for the fourth quarter and full year ended December 31, 2010, and Company guidance will be released after the closing of the market on Monday, March 28, 2011.  The timing of the earnings announcement allows MiMedx time to finalize the required two year audit of its recently acquired subsidiary, Surgical Biologics. The 8K/A filing of the audited financial statements of Surgical Biologics for the fiscal years ended December 31, 2010, and 2009, is due to be filed on Monday, March 14, 2011.

MiMedx Group will host a live broadcast of its 2010 results conference call on Tuesday, March 29, 2011, beginning at 10:30 a.m. Eastern Time.  A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com.  A 30-day online replay will be available on the Company's website at www.mimedx.com or at www.earnings.com approximately one hour following the conclusion of the live broadcast.

About MiMedx

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate sales growth and profitability.  Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures.  Our platform technologies, HydroFix™ and CollaFix™, and our newest platform processing technology, Purion®, developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures.  MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to accelerate commercialization of our technologies.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings
2. Native Americans descended from a single ancestral group, DNA study confirms
3. PNAS announces 6 2010 Cozzarelli Prize recipients
4. NIFA announces grants to study the effects of climate change on agricultural and forest production
5. FASEB announces the 2011 Summer Research Conference series: Registration is now open
6. Aware Announces Appointment of New Directors
7. Aware, Inc. Announces Q4 and FY2010 Earnings Conference Call
8. Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement
9. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
10. BTER Foundation announces winners of the William S. Baer Award
11. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology: